List of Figures
Figure 1: Neurodegenerative Disease, US, Innovation Trends in Product Approvals, 1987–2015 9
Figure 2: Neurodegenerative Disease, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 11
Figure 3: Neurodegenerative Disease, Global, Overview of Marketed Products, 2017 32
Figure 4: Neurodegenerative Disease, Global, Pipeline by Therapy Area, 2017 33
Figure 5: Neurodegenerative Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017 34
Figure 6: Neurodegenerative Disease, Global, Pipeline by Key Indications and Stage of Development, 2017 35
Figure 7: Neurodegenerative Disease, Global, Pipeline by Key Indications and Molecule Type, 2017 36
Figure 8: Neurodegenerative Disease, Global, Pipeline by Molecular Target and Stage of Development, 2017 38
Figure 9: Neurodegenerative Disease, Global, Pipeline Breakdown of Key Molecular Target Classes, 2017 39
Figure 10: Neurodegenerative Disease, Global, Pipeline Breakdown of Key Indications by Molecular Target Class, 2017 40
Figure 11: Neurodegenerative Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 41
Figure 12: Neurodegenerative Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 42
Figure 13: Neurodegenerative Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Key Indication, 2017 43
Figure 14: Neurodegenerative Disease, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class (%), 2017 43
Figure 15: Neurodegenerative Disease, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2017 44
Figure 16: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 1 45
Figure 17: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 2 46
Figure 18: Neurodegenerative Disease , Global, List of All Pipeline Programs, 2017 Part 3 47
Figure 19: Neurodegenerative Disease , Global, List of All Pipeline Programs, 2017 Part 4 48
Figure 20: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 5 49
Figure 21: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 6 50
Figure 22: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 7 51
Figure 23: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 8 52
Figure 24: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 9 53
Figure 25: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 10 54
Figure 26: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 11 55
Figure 27: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 12 56
Figure 28: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 13 57
Figure 29: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 14 58
Figure 30: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 15 59
Figure 31: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 16 60
Figure 32: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 17 61
Figure 33: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 18 62
Figure 34: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 19 63
Figure 35: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 20 64
Figure 36: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 21 65
Figure 37: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 22 66
Figure 38: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 23 67
Figure 39: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 24 68
Figure 40: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 25 69
Figure 41: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 26 70
Figure 42: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 27 71
Figure 43: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 28 72
Figure 44: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 29 73
Figure 45: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 30 74
Figure 46: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 31 75
Figure 47: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 32 76
Figure 48: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 33 77
Figure 49: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 34 78
Figure 50: Neurodegenerative Disease, Global, List of All Pipeline Programs, 2017 Part 35 79
Figure 51: Neurodegenerative Disease, Global, First-in-Class Molecular Target Matrix Assessment for Protein Misfolding, 2017 83
Figure 52: Neurodegenerative Disease Therapeutics Market, Global, First-in-Class Molecular Target Matrix Assessment for Neuromodulators, 2017 84
Figure 53: Neurodegenerative Disease Therapeutics Market, Global, First-in-Class Molecular Target Matrix Assessment for Immunomodulators, 2017 86
Figure 54: Neurodegenerative Disease Therapeutics Market, Global, First-in-Class Molecular Target Matrix Assessment for Neuroprotectants, 2017 87
Figure 55: Neurodegenerative Disease, Global, Industry-Wide Licensing Deals by Stage of Development and First-in-Class Status, 2006–2014 115
Figure 56: Neurodegenerative Disease, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006–2014 116
Figure 57: Neurodegenerative Disease, Global, Licensing Deals by Region, Value and Year, 2006–2017 117
Figure 58: Neurodegenerative Disease, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2017 118
Figure 59: Neurodegenerative Disease, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006–2017 119
Figure 60: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2017 120
Figure 61: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2017 121
Figure 62: Neurodegenerative Disease, Global, Co-development Deals by Region, Value and Year, 2006–2017 122
Figure 63: Neurodegenerative Disease, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2017 123
Figure 64: Neurodegenerative Disease, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006–2017 124
Figure 65: Neurodegenerative Disease, Global, Co-development Deals with Disclosed Deal Values, 2006–2017 125
Figure 66: Neurodegenerative Disease, Global, Co-development Deals with Disclosed Deal Values, 2006-2017 126
Figure 67: Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-development Deals, 2017, Part 1 128
Figure 68: Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-development Deals, 2017, Part 2 129
Figure 69: Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-development Deals, 2017, Part 3 130
Figure 70: Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-development Deals, 2017, Part 4 131
Figure 71: Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-development Deals, 2017, Part 5 132
Figure 72: Neurodegenerative Disease, Global, First-in-Class Pipeline Products with and without Prior Involvement in Licensing or Co-development Deals, 2017, Part 6 133
Figure 73: Neurodegenerative Disease, Global, Top 10 Ranked Matrix Targets in Alzheimer’s Disease, 2017 148
Figure 74: Neurodegenerative Disease, Global, Top 10 Ranked Matrix Targets in Parkinson’s Disease, 2017 149
Figure 75: Neurodegenerative Disease, Global, Top 10 Ranked Matrix Targets in Multiple Sclerosis, 2017 149